in Australia. Omeprazole is a proton pump inhibitor, and its oral dosage is currently considered the treatment of choice for ESGD and EGGD.
Provision of high-quality, evidence-based information as to when to withdraw omeprazole and other medications in horses in a training prior to a race day is a priority for horse racing regulators. A tenet of medication control in horse racing is that horses do not race under the pharmacological effects of drugs but are able to be treated with medication in training in the interests of their health and welfare.
Medication control involves screening blood or urine samples to detect parent drug or metabolites and is not usually an issue of drug detection, but about determining the concentration at which a drug no longer has a significant pharmacological effect in a population of horses. With omeprazole, this is complicated by the range of doses used, oral formulation, high interindividual variability (>30%) and mechanism of action of the drug.
Omeprazole is a prohibited substance according to the rules of the majority of racing jurisdictions with a wish to facilitate its use close to racing so that there is no recurrence of EGUS in susceptible horses whilst still not permitting racing under its direct effects. The European Horserace Scientific Liaison Committee (EHSLC) is a technical group representing European racing regulatory authorities who develop medication control advice in a harmonized way, based on detection
| Administrationstudy
Six Thoroughbred horses (one filly and five geldings) with a mean ± SD weight of 523.2 ± 26.1 kg, aged from 4 to 9 years, exercised in a manner consistent with that used in British training yards, fed a normal racehorse diet and housed at the British Horseracing Authority's Centre for Racehorse Studies (Newmarket, UK) were used for this study. The study was ethically approved with the horses, and personnel involved licensed under the UK Animals (Scientific Procedures) Act. A control blood sample and a urine sample were taken from each horse on each of 2 days preceding dosing and again immediately before the first dose, via an intravenous catheter (Milacath ® ) placed into the left jugular vein of each horse on that first day of dosing. A dose of 4 mg/kg of UlcerGold ® paste (37% w/w, Zoetis) was administered orally in five daily doses at 9 a.m. after a cereal-based racehorse mix had been given at 6 a.m. Hay was available ad lib. All the urine samples voided were collected following the first dose for 24 hr, immediately before each subsequent dose and following the final dose for up to 263 hr (12 days). Blood samples were collected immediately before each dose was administered and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 9, 11, 13 and 15 hr following the first and the final dose, as well as, 23, 31, 47, 71, 95, 119, 143, 167, 215 and 263 hr following the final dose.
Blood samples were collected in lithium heparin tubes and were centrifuged to separate plasma immediately after collection. Urine and plasma samples were stored at −20°C prior to analysis.
| Sampleanalysis
Plasma and urine samples were extracted and analysed using quantitative liquid chromatography-tandem mass spectrometry (LC-MS/ MS) methods, which had been validated for omeprazole using measures of linearity, intra-and interbatch precision and accuracy, specificity, selectivity and sensitivity (adhering to internal EHSLC quantitative method validation guidelines).
Plasma and urine detection methods were quantitatively validated in the ranges of 0.025-20 ng/ml and 0.1-20 ng/ml, respectively, and were shown to be linear with correlation coefficients greater than 0.99 when a weighting factor of 1/x was used. The methods for plasma and urine analysis were shown to be accurate and reproducible with low interbatch variability for precision (within ±7.0% for plasma and ±6.2%
for urine) and accuracy (within ±3.6% for both plasma and urine) at all QC concentrations (0.025, 0.075, 10 and 17 ng/ml in plasma and 0.1, 0.25, 10 and 17 ng/ml in urine). QC samples diluted 1 in 100 also produced acceptable results (within ±4.9% in plasma and ±13.0% in urine).
During plasma extraction, each batch included a calibration line in duplicate at concentrations of 0.025, 0.05, 0.1, 0.5, 1, 5, 10 and 20 ng/ml and QC samples in duplicate at concentrations of 0.075, 10 and 17 ng/ml. One millilitre of aliquots of plasma was spiked at a concentration of 100 ng/ml of omeprazole-d 3 . Plasma proteins were precipitated by addition of 0.5 ml of acetonitrile, and the sample was subsequently diluted with 7 ml of aqueous phosphate buffer (1 M, pH 6.8) and centrifuged at 1,960 g for 15 min. Solid phase extraction (SPE) was performed using Varian Nexus (60 mg, 3 ml) cartridges, which were conditioned with 2 ml of methanol followed by 2 ml of water prior to sample loading. Cartridges were washed with 1 ml of water prior to eluting with 1 ml of methanol: acetonitrile (60:40, v:v) .
During urine extraction, each batch included a calibration line in duplicate at concentrations of 0.1, 0.25, 0.5, 1, 2, 5, 10 and 20 ng/ ml and QC samples in duplicate at concentrations of 0.25, 10 and 17 ng/ml. One millilitre of aliquots of urine was spiked at a concentration of 100 ng/ml of omeprazole-d 3 . Samples were diluted with 1 ml of aqueous ammonium acetate buffer (0.1 M, pH 9.0). SPE was performed using Varian Nexus (60 mg, 3 ml) cartridges, which were conditioned with 2 ml of methanol followed by 2 ml of water prior to sample loading. Cartridges were washed with 2 ml of hexane prior to eluting with 2 ml of methanol: ethyl acetate (10:90, v:v) . Liquid-liquid extraction (LLE) was performed by adding 1.5 ml of purified water.
Following the extraction, both urine and plasma extracts were dried at ambient temperature under oxygen-free nitrogen and subsequently reconstituted in 100 μl of methanol and 100 μl of aqueous ammonium acetate buffer (10 mM, pH 6.8). Extracts were transferred into glass LC vials, and 5 μl was injected into the LC-MS/MS system.
Sample analysis was performed on a LC-MS/MS system consisting of a Waters Acquity I-Class UPLC interfaced with a Waters Xevo TQ-S triple quadrupole mass spectrometer operating in positive electrospray ionization mode at a capillary voltage of 2.0 kV, a source temperature of 150°C and a desolvation gas temperature at 550°C.
Collision gas was argon at a flow rate of 0.15 ml/min. Selected reaction monitoring ( Chromatographic separation was achieved on an Acquity HSS T3 (100 mm × 2.1 mm, 1.8 μm) reversed-phase UPLC column using ammonium acetate in methanol (10 mM, pH 6.8) and aqueous ammonium acetate (10 mM, pH 6.8) as mobile phases. A gradient was operated at 60°C and at a flow rate of 0.4 ml/min. It was started at 20% organic for 0.5 min followed by an increase to 99.9% organic at 5.5 min. This was held for 1 min before resuming the initial conditions and re-equilibrating for 1.5 min. The total run time was 8.5 min.
| Pharmacokineticevaluation
Pharmacokinetic parameters were estimated using noncompartmental analysis with Phoenix WinNonlin 6.0 (Pharsight Corporation, Cary, NC). The area under the plasma curve for the first 24 hr of postfinal dose (AUC 0-tau ) was calculated using the log-linear trapezoidal rule. The estimated average concentration at steady-state (C avg ) was determined from the AUC 0-tau divided by the dosing interval of 24 hr.
The methodology outlined by Toutain and Lassourd (2002) was used to estimate the effective plasma concentration (EPC), irrelevant plasma concentration (IPC), irrelevant urine concentration (IUC) and DT. The EPC was determined from the average steady-state plasma concentration (C avg,ss ) and estimated by dividing the AUC 0-24 for the last dose by the dosing interval (24 hr). The IPC creates the basis for the plasma SL, which is the concentration where the drug is no longer pharmacologically significant. The IPC was calculated by dividing the EPC by a safety factor of 500 to ensure there is no significant pharmacological effect for the majority of horses in a population.
| RESULTS

| Pharmacokineticanalysisfororally administeredomeprazoleinplasma
Omeprazole was detected in the postadministration plasma samples from all six horses (Figure 1 ). Maximum concentrations (C max ) were measured between 436 and 3,304 ng/ml between 0.5 and 4 hr (t max )
following either the first or final dose (Table 1 ). There was very little accumulation of omeprazole in plasma as shown by the trough levels, from the first dose through to fourth dose.
The terminal half-life (t 1/2 ) ranges from 6 to 18 hr, and the AUC 0-tau ranges from 1,476 to 4,371 ng hr ml
. The estimated mean and standard deviation for C avg,ss omeprazole concentration was 120 ± 46 ng/ml, which can be considered as the effective plasma concentration (EPC) for the 4 mg/kg once a day oral regimen in Thoroughbred horses. Different safety factors were applied to the EPC value to establish the appropriate irrelevant plasma concentration (IPC) ( Table 2) .
Using a safety factor of 500, the estimated IPC is 240 pg/ml with a corresponding DT of 47 hr.
| Pharmacokineticanalysisfororally administeredomeprazoleinurine
Omeprazole was detected in the postadministration samples from all six horses (Figure 2 ). The C max of omeprazole varied between 55 and F I G U R E 1 Plasma omeprazole concentrations versus time (semi-log) in six horses following the oral administration of UlcerGold ® for five consecutive daily doses the first or final dose administered (Table 3 ). The ISL of 500 pg/ml for omeprazole in urine was exceeded for up to 25 hr following the final dose, whilst detection was still possible at significantly lower concentrations for up to 71 hr postadministration.
| DISCUSSION
Omeprazole is a therapeutic drug which attracts debate with regard to its use in horse racing. In two studies which investigated omeprazole's effect on performance markers in healthy horses, no statistically sig- However, it has been shown to improve racing performance in the sense of returning a horse to a normal condition (Johnson et al., 2001) .
It therefore remains a therapeutic but prohibited substance on race day and is controlled via an ISL in urine with related DT advice in most racing jurisdictions.
This study set out to provide data to re-evaluate the existing international regulatory omeprazole DT advice, to re-evaluate the 430 and 379 (Jenkins et al., 1992) pg/ml using a safety factor of 500 for a dose of 4 mg/kg.
These values are higher but similar to the IPC determined from the oral pharmacokinetics determined in the herein study (240 pg/ml). (2015) and Di Salvo et al. (2017) studies which were also carried out at the same dose. However, a much higher plasma exposure (~10 times) was observed in these studies compared with the omeprazole serum exposure by Knych et al. (2017) at the same dose.
As SLs are calculated from drug exposure measurements at the therapeutic dose, the discrepancy between the study by Knych et al. (2017) and the other studies may make it difficult to harmonize SLs across racing jurisdictions. The only major difference between the Knych et al. (2017) study and the other studies is that serum concentrations were analysed for the former and plasma for the latter. The study by Knych et al. (2017) used serum separator tubes; one explanation for the apparent lower exposure may be that omeprazole diffused into the separating gel, causing a reduction in the measured serum drug concentration. Alternatively, serum concentration for omeprazole may be lower than the corresponding plasma concentration due to lower omeprazole binding to serum as part of the clotting process.
Omeprazole is known to have high plasma protein binding; however, a lower binding affinity to serum proteins will lead to a lower omeprazole serum concentration. In this case, a lower SL would be required for serum; however, further examination of the serum data suggests that the DT will be similar to the plasma studies based upon an irrelevant serum concentration.
One way forward with regard to generating an ISL in plasma for the oral administration of omeprazole is to use the IPC calculated from the published intravenous studies. In fact, Toutain and Lassourd (2002) recommend using intravenous data for the determination of the IPC; however, for omeprazole the intravenous studies are at a dose eight times smaller than those for the herein oral study.
Assuming dose-linear pharmacokinetics between 0.5 and 4 mg/kg, the IPC determined from the intravenous studies would encompass all oral formulations of omeprazole as it would represent the maximum exposure resulting from an oral administration (i.e., bioavailability = 100%).
Plasma data from the herein UlcerGold ® study show that omeprazole can be detected for up to 287 hr postadministration above the LLOQ of the 25 pg/ml of the method following an oral dose of 4 mg/ kg per day. However, the DT of 47 hr was determined using an IPC of 240 pg/ml. Previously, omeprazole has been detected in plasma for up to 24 hr postadministration when 4 mg/kg of GastroGard ® (37% w/w) was orally administered for 28 days (Hannan et al., 2008) . This shorter detection time was due to lower method sensitivity (LLOQ of 1 ng/ml). The results from these two studies are consistent as omeprazole was detected for up to 23 hr postadministration above the concentration of 1 ng/ml in the herein study.
A DT of 47 hr in plasma using an IPC of 240 pg/ml and a DT of 25 hr in urine using the ISL of 500 pg/ml were calculated for omeprazole based on six horses in this study. However, if a plasma screening limit of 500 pg/ml was applied, based upon the IPC determined from intravenous clearance, then the DT would be 31 hr. T A B L E 3 Summary of urine pharmacokinetic parameters for omeprazole following dose of 4 mg/kg once a day for five doses UlcerGold ® to six exercised Thoroughbred horses Interestingly, an IUC of 500 pg/ml can be estimated from this study by multiplying a plasma SL of 500 pg/ml by the urine to plasma steady-state omeprazole concentration ratio (R ss =1), which is in fact equal to (and therefore supports) the current urine ISL of 500 pg/ml for omeprazole. Tellez, Ocampo, Bernad, and Sumano (2005) have shown that a single oral 4 mg/kg dose of omeprazole (GastroGard ® ) increases stomach content pH above a control group for up to 24 hr. Furthermore, Merritt, Sanchez, Burrow, Church, and Ludzia (2003) have shown that 4 mg/ kg per day oral dose GastroGard ® for 7 days statistically increases intragastric pH for up to 14 hr relative to pre-administration on days 1 and 7. Daurio et al. (1999) showed a more pronounced effect using an oral paste formulation of omeprazole at 4 mg/kg, which inhibited both basal and pentagastrin-stimulated gastric acid secretion by 99%
at 5-8 hr after treatment and by 83% (basal) and 90% (pentagastrin- healed, or 100% improvement and 94% healed, respectively . The reported response rates for EGGD for oral omeprazole monotherapy are lower, with overall results at different doses (1, 2 and 4 mg/kg) showing 34% improvement and 14% complete healing . It is therefore desirable that as far as possible within the principle of racing without the benefit of drugs, horses that need to be treated with omeprazole are treated in the confidence that they will neither risk a postrace adverse analytical finding ("positive") nor have their health compromised. The new data reported herein for orally administered, in conjunction with other published studies, suggest that a plasma SL of 500 pg/ml should be used in addition to the existing urine ISL of the same concentration. A detection time of 48 hr is recommended which should assist those balancing what is best for an individual horse with what is needed to protect the integrity of the sport in which they are involved.
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